Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1.-46. (canceled)

47. (currently amended) A method of treating a malignant tumor in a human patient comprising co-administering to the patient

(a) a composition comprising a therapeutically effective amount of human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as ~~a~~ the malignant tumor of ~~a~~ said patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein; and

(b) an adjuvant;

~~wherein said composition elicits at least one of the following upon administration to said patient with the adjuvant: an inflammatory immune response against the tumor of said patient; a delayed type hypersensitivity response against the tumor of said patient and activated T lymphocytes that infiltrate the tumor of said patient; and~~ wherein said malignant tumor is from a cancer selected from the group consisting of melanoma cancer, lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer;

repeating said administration ~~at least six times at spaced apart intervals~~ of said composition for a total of at least six administrations of said composition; and

administering a therapeutically effective amount of cyclophosphamide to the patient only prior to the first administration of said composition.

48-66. (canceled)

67. (previously presented) The method of claim 47, wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1 -naphtyl) ethylene diamine.

68. (previously presented) The method of claim 47 wherein said hapten is dinitrophenyl.

69. (canceled)

70. (currently amended) The method of claim 47, ~~further comprising~~ wherein administering a therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M^2 of cyclophosphamide prior to the first administration of said composition.

71. (canceled)

72. (previously presented) The method of claim 47 further comprising sensitizing the patient with a therapeutically effective amount of 1 -fluoro-2,4-dinitrobenzene prior to administering cyclophosphamide.

73. (canceled)

74. (previously presented) The method of claim 47 wherein said adjuvant is Bacillus Calmette-Guerin.

75. (currently amended) The method of claim 47 wherein said administration of said composition prolongs survival of said patient.

76. (canceled)

77. (currently amended) The method of claim 47, wherein said administration of said composition elicits T lymphocytes that infiltrate the tumor of said human~~, said lymphocytes being predominantly CD8 + CD4~~.